Brief: Dimerix Says Dmx-200 Receives Orphan Drug Designation In Japan
30/09/2025 02:23
Sept 30 (Reuters) - Dimerix Ltd DXB.AX: DMX-200 RECEIVES ORPHAN DRUG DESIGNATION IN JAPAN Further company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions